Compare D R Horton Inc (DHI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs GeneDx Holdings Corp — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: D R Horton Inc is far larger — about 18.8× GeneDx Holdings Corp's market cap, and D R Horton Inc pays a 1.33% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| DHI | WGS | |
|---|---|---|
Market Cap | $37.99B | $2.02B |
Volume | 2,974,460 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $167.51 |
52-Week Low | $132.53 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $43.09B | $2.05B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from rising mortgage rates impacting the housing sector, with revenue declining to $34.25B in 2025 and net income margin compressing to 9.15%. Analyst consensus remains positive with a $156.57 price target, but technical indicators show resistance at $137 with support at $133.
The outlook is mixed with strong fundamentals and attractive valuation (P/E 12.95) offset by macroeconomic pressures on housing demand. Key risks include persistent high interest rates and housing market volatility, while institutional sentiment leans bullish with 47% buy ratings. The stock offers value for long-term investors but faces near-term sector headwinds.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
